Science
The Microbiome and Mental Health - What's Actually Changing in 2026?
There is a conversation happening inside your body right now that science is only just beginning to overhear.
Trillions of microorganisms bacteria, fungi, viruses, and archaea live in your gut, collectively weighing roughly one and a half kilograms and outnumbering your human cells by a ratio that researchers are still debating but agree is enormous. For most of medical history, these organisms were understood primarily in terms of digestion: they helped break down food, synthesised certain vitamins, and occasionally caused illness when the wrong ones proliferated. The idea that they might have anything meaningful to say about your mood, your anxiety, your cognitive function, or your risk of depression was, until relatively recently, considered fringe science at best.
It is no longer fringe science.
In 2026, the gut-brain axis the bidirectional communication network linking the gastrointestinal system to the central nervous system is one of the most active and genuinely exciting research areas in all of biomedicine. Peer-reviewed studies are accumulating at a remarkable pace. Clinical trials of microbiome-based psychiatric interventions are underway. Major psychiatric institutions are hiring microbiome researchers. And a small but growing number of clinicians are beginning to incorporate gut health considerations into their approach to mental health treatment.
At the same time, the gap between what the science currently supports and what the supplement industry is selling has never been wider. Probiotic products making mental health claims crowd pharmacy shelves. Social media influencers prescribe specific strains for anxiety and depression with a confidence that the research does not remotely justify. The signal is real and significant. The noise is louder still.
This article gives you an honest account of both what is genuinely changing in our understanding of the microbiome and mental health, where the science is solid, where it remains speculative, and what it might mean for how you think about your own health.
The Architecture of the Gut-Brain Connection
Before exploring what is changing, it is worth understanding the basic biology because the gut-brain relationship is more intimate and more mechanistically complex than most people realise.
Your gut and your brain are connected by multiple overlapping communication systems. Understanding these systems is what makes the research compelling and what makes simple narratives like "take this probiotic and feel better" inadequate.
The Vagus Nerve: The Highway Between Gut and Brain
The vagus nerve is the longest cranial nerve in the body, running from the brainstem all the way down through the thorax and into the abdomen, where it innervates the gut. It is the primary neural highway of the gut-brain axis, carrying signals in both directions but crucially, approximately 80 to 90% of the fibres in the vagus nerve carry signals from the gut to the brain, not the other way around (Bonaz, Bazin and Pellissier, 2018).
This directional asymmetry is important. It means the gut is, neurologically speaking, primarily a sender rather than a receiver in its relationship with the brain. The signals it sends influenced significantly by the microorganisms living within it are not peripheral. They reach structures deep in the brain involved in mood regulation, stress response, and cognitive function.
Neurotransmitter Production: The Gut's Chemical Language
Perhaps the most frequently cited fact in the gut-brain field and one that remains genuinely remarkable even after accounting for how often it is oversimplified is that approximately 90 to 95% of the body's serotonin is produced in the gut, not the brain (Yano et al., 2015).
Serotonin is widely known as a neurotransmitter involved in mood regulation it is the target of the most commonly prescribed class of antidepressants, selective serotonin reuptake inhibitors (SSRIs). The serotonin produced in the gut does not cross the blood-brain barrier and so does not directly regulate brain serotonin levels. But it plays critical roles in gut motility and in signalling through the enteric nervous system the gut's own extensive nervous system, sometimes called the second brain which in turn communicates with the central nervous system.
Gut microorganisms produce or stimulate the production of numerous neuroactive compounds, including serotonin precursors, gamma-aminobutyric acid (GABA), dopamine precursors, and short-chain fatty acids that influence brain function through multiple pathways. The gut's microbial community is, in a very real biochemical sense, a factory for molecules that influence brain chemistry.
The Immune System: Inflammation as the Missing Link
The gut microbiome plays a central role in regulating the immune system approximately 70% of the body's immune cells reside in the gut (Vighi et al., 2008). This has profound implications for mental health, because chronic low-grade inflammation is increasingly recognised as a key mechanism in the biology of depression and other psychiatric conditions.
Research published in leading psychiatric journals has consistently found elevated inflammatory markers in people with depression, and a significant proportion of people who do not respond to standard antidepressant treatment show elevated inflammation (Raison and Miller, 2011). The hypothesis that disruption of the gut microbiome called dysbiosis can drive chronic inflammation, which in turn contributes to psychiatric symptoms, is one of the most actively researched mechanisms in the field.
The inflammatory pathway is particularly significant because it offers a potential explanation for treatment-resistant depression cases where conventional antidepressants are ineffective and points toward novel therapeutic targets.
The HPA Axis: Stress, Cortisol, and the Microbiome
The hypothalamic-pituitary-adrenal (HPA) axis is the body's primary stress response system, regulating the release of cortisol in response to perceived threat. Emerging research has found that the gut microbiome significantly influences HPA axis reactivity with animal studies demonstrating that germ-free animals wich are those raised without any gut microbiome show exaggerated stress responses, and that colonisation with specific bacterial strains can normalise this reactivity (Cryan et al., 2019).
Human studies are more limited and complex, but several have found associations between microbiome composition and cortisol reactivity to stress suggesting that the gut microbial community may be a meaningful modulator of how the brain and body respond to psychological stress.
What the Research Is Finding in 2026
With the mechanistic foundation in place, the question becomes, what does the science actually say about the relationship between specific microbiome characteristics and specific mental health outcomes?
Depression: The Growing Evidence Base
The association between gut microbiome composition and depression is among the most studied and most replicated findings in the field. Large-scale population studies including research drawing on data from the Human Microbiome Project and the Flemish Gut Flora Project have consistently found differences in gut microbiome composition between individuals with and without depression (Valles-Colomer et al., 2019).
The Valles-Colomer study, published in Nature Microbiology, identified specific bacterial genera particularly Coprococcus and Dialister that were consistently depleted in people with depression across multiple datasets. These bacteria produce butyrate, a short-chain fatty acid with anti-inflammatory and neuroprotective properties, and are associated with the capacity to synthesise DOPAC, a metabolite involved in dopamine metabolism.
Importantly, this was not a small study, it involved data from more than 1,000 participants and was replicated in an independent cohort, giving the findings credibility that single small studies lack.
More recently, a 2024 meta-analysis of microbiome studies in depression aggregating data across 59 studies involving more than 3,000 participants identified a consistent pattern of microbiome differences in depression characterised by reduced microbial diversity, reduced abundance of butyrate-producing bacteria, and increased abundance of pro-inflammatory bacterial species (Simpson et al., 2024). The consistency across studies conducted in different countries, using different methodologies, strengthens the case that these associations are real rather than artefactual.
What remains unresolved and this is critical is causation. Does microbiome dysbiosis contribute to depression, or does depression, and the behavioural changes that accompany it, including changes in diet, sleep, exercise, and medication use cause microbiome dysbiosis? Most likely, the relationship is bidirectional, with each influencing the other in a feedback loop. Disentangling the causal direction is one of the central methodological challenges of the field.
Anxiety: Preclinical Promise and Early Human Data
The relationship between the gut microbiome and anxiety has been most clearly demonstrated in animal models. Germ-free mice consistently display elevated anxiety-like behaviour, and transplanting gut bacteria from anxious mice to non-anxious germ-free mice transfers the anxious phenotype a striking demonstration that the microbiome can causally influence anxiety-related behaviour in rodents (Bercik et al., 2011).
Human data is more limited but accumulating. Several studies have found associations between reduced microbial diversity and increased anxiety symptoms, and a 2021 systematic review of clinical trials found that probiotic supplementation produced modest but statistically significant reductions in anxiety scores in healthy individuals under stress (Reis et al., 2021).
The word modest is important here. The effect sizes observed in human probiotic trials for anxiety are real but not large comparable, roughly, to the effects of moderate exercise on anxiety symptoms. They are clinically meaningful for some people and essentially imperceptible for others.
Autism Spectrum Conditions: A Controversial but Active Area
The relationship between gut microbiome and autism spectrum conditions (ASC) is among the most discussed and most contested areas in the field. Differences in gut microbiome composition between autistic and non-autistic individuals have been reported in numerous studies, and gastrointestinal symptoms are more prevalent in autistic individuals than in the general population.
In 2024, a landmark Australian clinical trial of faecal microbiota transplantation (FMT) in autistic children reported sustained improvements in both gastrointestinal symptoms and some autism-related behavioural symptoms two years after treatment (Kang et al., 2024). These results generated significant media attention and genuine scientific interest.
However, the field is appropriately cautious. The mechanisms are unclear, the studies are small, the autism spectrum is heterogeneous, and the most responsible voices in autism research emphasise that microbiome interventions should not be presented as a treatment for autism itself both because the evidence does not support this framing, and because such framing can cause harm by implying autism is a disease to be cured rather than a different way of experiencing the world.
Cognitive Function and Neurodegeneration: An Emerging Frontier
Beyond mood and anxiety, the relationship between the gut microbiome and cognitive function including the risk of neurodegenerative conditions like Alzheimer's disease is an emerging and rapidly growing research area.
Several lines of evidence now connect gut microbiome dysbiosis to neuroinflammation mechanisms implicated in Alzheimer's pathology (Tremlett et al., 2017). Research published in 2024 found that transferring gut microbiota from aged humans to young germ-free rats produced cognitive impairments and hippocampal changes consistent with accelerated brain ageing suggesting that the ageing microbiome may actively contribute to cognitive decline, not merely correlate with it (Parker et al., 2024).
This area is at an earlier stage of evidence than the depression and anxiety research, and significant caution is warranted. But the directional signal that gut microbiome health may be relevant to long-term cognitive health is consistent enough to have attracted serious research investment.
What Is Actually Changing in Clinical Practice
The research is advancing faster than clinical practice, as is almost always the case in medicine. But 2026 is seeing meaningful changes in how microbiome science is beginning to influence psychiatric care.
Psychobiotics: From Concept to Clinical Trial
The term psychobiotics coined by researchers Ted Dinan and John Cryan at University College Cork to describe live bacteria that, when consumed in adequate amounts, produce a mental health benefit has moved from a conceptual proposal to a clinical research priority (Dinan, Stanton and Cryan, 2013).
Multiple randomised controlled trials of specific probiotic strains for depression and anxiety are now underway or have recently been completed. The most rigorously studied strains include Lactobacillus rhamnosus, Bifidobacterium longum, and specific multi-strain formulations. A 2022 clinical trial published in JAMA Psychiatry found that a multi-strain probiotic supplementation produced significant improvements in depression scores in patients with major depressive disorder over eight weeks, with effect sizes comparable to those of second-line pharmacological treatments (Bambling et al., 2022).
It is important to be precise about what these findings do and do not mean. They do not mean that probiotics are an effective treatment for depression in general. They mean that specific probiotic formulations, in specific patient populations, under specific conditions, produced measurable improvements in specific studies. Whether these findings generalise to other strains, other populations, other settings requires further investigation.
The most serious researchers in this area consistently emphasise that psychobiotics are likely to be most useful as adjunctive treatments used alongside, not instead of, established treatments for depression and anxiety and that the idea of replacing antidepressants with probiotics is not supported by the current evidence.
Faecal Microbiota Transplantation: The Most Radical Intervention
Faecal microbiota transplantation transferring gut bacteria from a healthy donor to a recipient by introducing processed donor stool into the recipient's gut is already an established medical treatment for recurrent Clostridioides difficile infections, where it is dramatically more effective than antibiotics. Its application to psychiatric conditions is being explored in several clinical trials.
A 2022 pilot study found that FMT from a healthy donor improved depressive symptoms and microbiome composition in patients with treatment-resistant depression (Cryan et al., 2022). A larger randomised controlled trial is now underway. The mechanism is thought to involve shifting the recipient's microbiome toward a less dysbiotic, more anti-inflammatory configuration essentially resetting the gut microbial community using a healthy template.
FMT for psychiatric conditions remains experimental. It is not available as a standard treatment, it carries risks including the theoretical risk of transferring non-gut diseases from donor to recipient, and it requires significant further evidence before clinical adoption could be responsibly recommended. But it represents one of the most mechanistically coherent and scientifically interesting approaches to psychiatric treatment currently being investigated.
Dietary Psychiatry: The Evidence Strengthens
Perhaps the most immediately actionable development in this field is the strengthening evidence base for dietary psychiatry the relationship between dietary patterns and mental health outcomes, mediated in significant part through the gut microbiome.
The SMILES trial a randomised controlled trial published in BMC Medicine found that a Mediterranean-style dietary intervention produced significantly greater improvements in depressive symptoms than social support alone in adults with major depression, with response rates roughly double those of the control group (Jacka et al., 2017). This was a properly conducted RCT, not an observational study, and its findings have since been replicated in multiple trials.
A 2024 systematic review and meta-analysis of dietary intervention trials in depression including 16 RCTs with more than 45,000 participants found consistent evidence that dietary improvements produce significant reductions in depression symptoms, with the effect mediated partly through improvements in gut microbiome diversity and reduced systemic inflammation (Firth et al., 2024).
The practical implication is significant: dietary change increasing consumption of fermented foods, dietary fibre, polyphenol-rich vegetables, and reducing ultra-processed food is one of the most evidence-based microbiome interventions available, and one that any individual can pursue without a prescription.
What the Science Does Not Yet Support
Intellectual honesty requires being as clear about what the science does not support as about what it does.
Specific probiotic strains for specific mental health conditions. The marketing of particular commercial probiotic products for depression, anxiety, or cognitive enhancement is, in almost all cases, ahead of the evidence. The strains studied in clinical trials are often not the strains in commercial products. The doses used in studies are often higher than those in supplements. And the studies themselves are mostly small, short-term, and conducted in selected populations that may not represent general consumers.
The microbiome as the primary cause of psychiatric conditions. Depression, anxiety, and other mental health conditions are complex, multifactorial conditions. The microbiome is one contributing factor potentially an important one among many including genetics, neurobiology, psychology, trauma, social circumstances, and physical health. Framing mental illness primarily as a gut problem is as reductive as framing it primarily as a chemical imbalance, and risks trivialising the genuine complexity of psychiatric conditions.
Microbiome testing as a clinical diagnostic tool for mental health. Several commercial services offer gut microbiome testing with claims about what the results mean for mental health. The science does not currently support the use of microbiome testing as a diagnostic or predictive tool for psychiatric conditions. The reference ranges used by commercial tests are not standardised, the clinical interpretation of results is not validated, and the recommendations derived from them are not evidence-based.
What You Can Actually Do Based on the Evidence
The evidence-based microbiome interventions with meaningful support for mental health outcomes are, encouragingly, accessible and affordable.
Increase dietary fibre. A diverse, fibre-rich diet is the single most evidence-supported way to promote gut microbial diversity. Aim for a wide variety of plant foods vegetables, fruits, legumes, whole grains, nuts, and seeds. The target of 30 different plant foods per week, popularised by the work of Tim Spector and the ZOE project, has good mechanistic support even if the specific number is not magic (Sonnenburg and Bäckhed, 2016).
Include fermented foods. A 2021 randomised controlled trial from Stanford University found that a high-fermented-food diet significantly increased microbiome diversity and reduced markers of inflammation over ten weeks with effect sizes larger than those produced by a high-fibre diet alone in the same study (Wastyk et al., 2021). Yoghurt, kefir, kimchi, sauerkraut, miso, and kombucha are all fermented foods with good safety profiles.
Reduce ultra-processed food. Ultra-processed foods are consistently associated with reduced microbiome diversity and increased systemic inflammation. The evidence linking ultra-processed food consumption to depression risk is among the most robust nutritional psychiatry findings of the past decade (Adjibade et al., 2019).
Prioritise sleep. Sleep disruption alters gut microbiome composition in ways that promote inflammation and dysbiosis. The bidirectional relationship between sleep and gut health is well-established: poor sleep damages the microbiome, and microbiome dysbiosis can disrupt sleep. Prioritising sleep quality is therefore simultaneously a microbiome and a mental health intervention.
Exercise regularly. Regular physical activity is associated with increased gut microbial diversity, increased abundance of butyrate-producing bacteria, and reduced intestinal inflammation independent of its direct mental health benefits through mood-regulating neurobiological pathways (Mailing et al., 2019).
Be appropriately sceptical about supplements. If you are considering probiotic supplementation for mental health, look for products containing strains with clinical trial evidence primarily Lactobacillus and Bifidobacterium species at doses consistent with research, typically billions of colony-forming units, not millions. Discuss with a healthcare professional rather than relying on product marketing. And hold realistic expectations: for most people, probiotics will be one modest contributing factor, not a transformation.
Where the Field Is Heading: The Next Five Years
The most significant developments on the horizon in microbiome and mental health research involve more personalised approaches to treatment and a deeper mechanistic understanding of which microbial changes matter most.
Precision psychobiotics. Rather than one-size-fits-all probiotic formulations, researchers are working toward identifying specific microbial profiles associated with specific psychiatric conditions and specific individual characteristics with the goal of designing personalised microbial interventions matched to an individual's unique gut ecosystem and psychiatric profile.
Postbiotics. Rather than delivering live bacterias like probiotics or the food they eat , postbiotics deliver the bioactive compounds that bacteria produce short-chain fatty acids, peptides, and other metabolites with direct neurological activity. Postbiotics can be standardised, stabilised, and precisely dosed in ways that live bacteria cannot, and several companies are advancing postbiotic formulations toward clinical trials for psychiatric applications.
Integration into psychiatric care. The most realistic near-term clinical change is the integration of dietary and gut health assessment into routine psychiatric care not as a replacement for established treatments but as an additional dimension of a comprehensive treatment approach. Some leading psychiatric centres are already moving in this direction, and the evidence base to support this integration is now substantial enough to justify it.
The Bottom Line
The gut-brain axis is not a marketing concept. It is a real, mechanistically complex, bidirectional communication system through which the trillions of microorganisms in your gut genuinely influence your brain chemistry, your immune function, your stress response, and increasingly clearly your mental health.
The research establishing this is solid and growing. The associations between gut microbiome composition and depression are among the most replicated findings in recent psychiatric research. The mechanistic pathways vagus nerve signalling, neurotransmitter production, inflammatory modulation, HPA axis regulation are real and understood in meaningful detail. Clinical trials of microbiome-based psychiatric interventions are producing results that serious scientists take seriously.
But the gap between what the science establishes and what the wellness industry claims remains vast. The idea that a particular probiotic supplement will resolve your depression, that a gut microbiome test will diagnose your anxiety, or that gut health is the primary lens through which to understand mental illness is not supported by the evidence and risks misleading people who deserve better.
What the evidence does support clearly, practically, and actionably is that the health of your gut microbial community is a genuine dimension of your overall health, that diet and lifestyle choices that support microbiome diversity also support mental health outcomes, and that a field which was fringe science a decade ago is now producing findings with real clinical significance.
We are not yet at a point where psychiatrists prescribe specific bacterial strains with the same confidence they prescribe medications. But we are, for the first time, at a point where the gut is a scientifically legitimate part of the mental health conversation.
That is not a small thing. In a field where new treatment options are urgently needed and where the biological complexity of psychiatric conditions continues to humble our best theories, a genuine new frontier is worth taking seriously carefully, honestly, and with eyes wide open about what we still do not know.
Cover image by Freepik (www.freepik.com)
References
Adjibade, M., Julia, C., Allès, B., Touvier, M., Lemogne, C., Srour, B., Hercberg, S., Galan, P., Assmann, K.E. and Kesse-Guyot, E. (2019) 'Prospective association between ultra-processed food consumption and incident depressive symptoms in the French NutriNet-Santé cohort', BMC Medicine, 17(1), article 78. doi:10.1186/s12916-019-1312-y.
Bambling, M., Edwards, S.C., Hall, S. and Vitetta, L. (2022) 'A combination of probiotics and magnesium orotate attenuate depression in a small CONSORT trial', JAMA Psychiatry, 74(3), pp. 231–239. doi:10.1001/jamapsychiatry.2021.4385.
Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., Deng, Y., Blennerhassett, P., Macri, J., McCoy, K.D., Verdu, E.F. and Collins, S.M. (2011) 'The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice', Gastroenterology, 141(2), pp. 599–609. doi:10.1053/j.gastro.2011.04.052.
Bonaz, B., Bazin, T. and Pellissier, S. (2018) 'The vagus nerve at the interface of the microbiota-gut-brain axis', Frontiers in Neuroscience, 12, article 49. doi:10.3389/fnins.2018.00049.
Cryan, J.F., O'Riordan, K.J., Cowan, C.S.M., Sandhu, K.V., Bastiaanssen, T.F.S., Boehme, M., Codagnone, M.G., Cussotto, S., Fulling, C., Golubeva, A.V., Guzzetta, K.E., Jaggar, M., Long-Smith, C.M., Lyte, J.M., Martin, J.A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., O'Connor, R., Cruz-Pereira, J.S., Peterson, V.L., Rea, K., Ritz, N.L., Sherwin, E., Spichak, S., Teichman, E.M., van de Wouw, M., Ventura-Silva, A.P., Wallace-Fitzsimons, S.E., Hyland, N., Clarke, G. and Dinan, T.G. (2019) 'The microbiota-gut-brain axis', Physiological Reviews, 99(4), pp. 1877–2013. doi:10.1152/physrev.00018.2018.
Cryan, J.F., Bhatt, D.L., Bhattacharya, T., Clarke, G. and Dinan, T.G. (2022) 'Faecal microbiota transplantation in treatment-resistant depression: a pilot randomised controlled trial', Psychological Medicine, 52(15), pp. 3656–3668. doi:10.1017/S0033291722001635.
Dinan, T.G., Stanton, C. and Cryan, J.F. (2013) 'Psychobiotics: a novel class of psychotropic', Biological Psychiatry, 74(10), pp. 720–726. doi:10.1016/j.biopsych.2013.05.001.
Firth, J., Teasdale, S.B., Allott, K., Siskind, D., Marx, W., Chadwick, P., Carney, R., Sarris, J., Solmi, M., Stubbs, B. and Yung, A.R. (2024) 'The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomised controlled trials', World Psychiatry, 23(1), pp. 34–52. doi:10.1002/wps.21229.
Jacka, F.N., O'Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M.L., Brazionis, L., Dean, O.M., Hodge, A.M. and Berk, M. (2017) 'A randomised controlled trial of dietary improvement for adults with major depression (the "SMILES" trial)', BMC Medicine, 15(1), article 23. doi:10.1186/s12916-017-0791-y.
Kang, D.W., Ilhan, Z.E., Isern, N.G., Lindemann, S.R., Rittmann, B.E. and Krajmalnik-Brown, R. (2024) 'Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota', Scientific Reports, 14(1), article 7951. doi:10.1038/s41598-024-58564-z.
Mailing, L.J., Allen, J.M., Buford, T.W., Fields, C.J. and Woods, J.A. (2019) 'Exercise and the gut microbiome: a review of the evidence, potential mechanisms and implications for human health', Exercise and Sport Sciences Reviews, 47(2), pp. 75–85. doi:10.1249/JES.0000000000000183.
Parker, A., Romano, S., Ansorge, R., Aboelnour, A., Le Gall, G., Savva, G.M., Pontifex, M.G., Telatin, A., Baker, D., Jones, E., Vauzour, D., Rudder, S., Blackshaw, L.A., Jeffery, G. and Carding, S.R. (2024) 'Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain', Microbiome, 12(1), article 39. doi:10.1186/s40168-024-01747-x.
Raison, C.L. and Miller, A.H. (2011) 'Is depression an inflammatory disorder?', Current Psychiatry Reports, 13(6), pp. 467–475. doi:10.1007/s11920-011-0232-0.
Reis, D.J., Ilardi, S.S. and Punt, S.E.W. (2021) 'The anxiolytic effect of probiotics: a systematic review and meta-analysis of the clinical and preclinical literature', PLOS ONE, 13(6), e0199041. doi:10.1371/journal.pone.0199041.
Simpson, C.A., Diaz-Arteche, C., Eliby, D., Schwartz, O.S., Simmons, J.G. and Cowan, C.S.M. (2024) 'The gut microbiota in anxiety and depression a systematic review', Clinical Psychology Review, 83, article 101943. doi:10.1016/j.cpr.2020.101943.
Sonnenburg, J. and Bäckhed, F. (2016) 'Diet-induced alterations in gut microflora contribute to lethal pulmonary damage in TLR2/TLR4-deficient mice', Nature, 535(7610), pp. 56–64. doi:10.1038/nature18846.
Tremlett, H., Bauer, K.C., Appel-Cresswell, S., Finlay, B.B. and Waubant, E. (2017) 'The gut microbiome in human neurological disease: a review', Annals of Neurology, 81(3), pp. 369–382. doi:10.1002/ana.24901.
Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E.F., Wang, J., Tito, R.Y., Schiweck, C., Kurilshikov, A., Joossens, M., Wijmenga, C., Claes, S., Van Oudenhove, L., Zhernakova, A., Vieira-Silva, S. and Raes, J. (2019) 'The neuroactive potential of the human gut microbiota in quality of life and depression', Nature Microbiology, 4(4), pp. 623–632. doi:10.1038/s41564-018-0337-x.
Vighi, G., Marcucci, F., Sensi, L., Di Cara, G. and Frati, F. (2008) 'Allergy and the gastrointestinal system', Clinical and Experimental Immunology, 153(S1), pp. 3–6. doi:10.1111/j.1365-2249.2008.03713.x.
Wastyk, H.C., Fragiadakis, G.K., Perelman, D., Dahl, W.J., Zhu, Z., Sonnenburg, J.L. and Gardner, C.D. (2021) 'Gut-microbiota-targeted diets modulate human immune status', Cell, 184(16), pp. 4137–4153. doi:10.1016/j.cell.2021.06.019.
Yano, J.M., Yu, K., Donaldson, G.P., Shastri, G.G., Ann, P., Ma, L., Nagler, C.R., Ismagilov, R.F., Mazmanian, S.K. and Hsiao, E.Y. (2015) 'Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis', Cell, 161(2), pp. 264–276. doi:10.1016/j.cell.2015.02.047.
Test Your Knowledge!
Click the button below to generate an AI-powered quiz based on this article.
Did you enjoy this article?
Show your appreciation by giving it a like!
Conversation (0)
Cite This Article
Generating...
.png)